Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-Dose Fasting Bioequivalence Study of Letrozole Tablets (2.5 mg; Mylan) and Femara® Tablets (2.5 mg; Novartis) in Healthy Postmenopausal Female Volunteers

NCT00648063 is registered in ClinicalTrials.gov with Mylan Pharmaceuticals Inc as lead sponsor.

NCT NCT00648063
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00648063 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-Dose Fasting Bioequivalence Study of Letrozole Tablets (2.5 mg; Mylan) and Femara® Tablets (2.5 mg; Novartis) in Healthy Postmenopausal Female Volunteers
Lead sponsor
Mylan Pharmaceuticals Inc
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2005
Completion date
January 31, 2006
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy